Answers are grounded in this paper and cite their sources.
Emergency efforts are underway to find optimum medical products to prevent infection and diagnose and treat patients during the coronavirus disease 2019 (COVID-19) pandemic. Production and supply chains for COVID-19 candidate drugs (such as chloroquine and hydroxychloroquine), and for many other essential medical products, are being impaired by this crisis.1 Supply chains for vital drugs for other diseases (such as systemic lupus erythematosus) are being disrupted because they are being repurposed to use against COVID-19, without adequate supporting evidence.
No takes yet. Share an insight, caveat, or question.
Newton et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: